Type II ROS1 Inhibition Overcomes Type I Inhibitor Resistance in ROS1 Fusion-Positive Lung Cancers: A Phase II Trial of Cabozantinib. (PubMed, Clin Cancer Res) - Oct 6, 2026 - P2 | "Cabozantinib achieved responses in pre-treated ROS1 fusion-positive NSCLCs, even in the presence of multi-drug-resistant mutations, highlighting the potential utility of type II ROS1 TKI therapy."
Journal • P2 data • Cardiovascular • Dermatology • Fatigue • Hypertension • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MET • ROS1
|
|
Alexander Drilon; Christina Falcon; Clare Wilhelm; Guilherme Harada; Jaime Rubio-Perez; Jeeban P Das; Ling Feng Ye; Mark G Kris; Matteo Repetto; Meghanne Lomibao; Rebecca Repetti
|